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G-protein-coupled bile acid receptor, Gpbar1 (TGR5), is a member of G-protein-coupled
receptor (GPCR) superfamily. High levels of TGR5mRNAwere detected in several tissues
such as small intestine, stomach, liver, lung, especially in placenta and spleen. TGR5 is
not only the receptor for bile acids, but also the receptor for multiple selective synthetic
agonists such as 6α-ethyl-23(S)-methyl-cholic acid (6-EMCA, INT-777) and a series of
4-benzofuranyloxynicotinamde derivatives to regulate different signaling pathways such
as nuclear factor κB (NF-κB), AKT, and extracellular signal-regulated kinases (ERK).
TGR5, as a metabolic regulator, is involved in energy homeostasis, bile acid homeostasis,
as well as glucose metabolism. More recently, our group and others have extended
the functions of TGR5 to more than metabolic regulation, which include inflammatory
response, cancer and liver regeneration. These findings highlight TGR5 as a potential
drug target for different diseases. This review summarizes the basic information of TGR5
and its new functions.
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INTRODUCTION
G-protein-coupled receptors (GPCRs) are large family of receptors, playing important roles in
multiple pathways (Cvijic et al., 2015). They contain seven transmembrane domains. Upon binding
of ligands in the extracellular space, GPCRs transduce the extracellular signal to intracellular
downstream cascades through activating multiple effector pathways (Rohrer and Kobilka, 1998).
Because of the important functions of GPCR in different cell signaling pathways, they have become
attractive targets for treatment of many diseases.
TGR5, as a member of GPCRs, was discovered in 2002 (Maruyama et al., 2002). It was classified
as the founder member of the bile acid receptor subclass of GPCRs (Foord et al., 2005). TGR5
gene locates on chromosome position 2q35 in humans. Its open reading frame has 993 base pairs,
encoding 330 amino acids. High levels of TGR5 mRNA were detected in several organs such as
small intestine, stomach, liver, lung, especially placenta and spleen (Keitel et al., 2007; Tiwari and
Maiti, 2009). TGR5 can be activated by bile acids and then it induces cAMP production (Maruyama
et al., 2002). As a membrane receptor, TGR5 can be internalized into the cytoplasm in response to
its ligands (Kawamata et al., 2003). TGR5 plays important roles in cell signaling pathways such as
nuclear factor κB (NF-κB) (Meng et al., 2011), AKT (Kida et al., 2013), and extracellular signal-
regulated kinases (ERK) (Masyuk et al., 2013). Its agonists may be potential drugs for treatment of
metabolic, inflammation and digestive disorders (Kumar et al., 2012; Broeders et al., 2015).
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Activation of TGR5 has shown promise in treating various
metabolic diseases such as type 2 diabetes (T2D) and obesity.
Its activation also mediates novel effects on inflammation and
cancer in different organs. In this review, we summarize the basic
properties of TGR5 including its ligands and basic functions.
Specifically, we will discuss the new findings about TGR5 in
different signaling pathways and diseases.
THE LIGANDS OF TGR5
As a plasma membrane-bound GPCR, the endogenous
natural agonists of TGR5 are bile acids. Taurolithocholic acid
(TLCA), lithocholic acid (LCA), deoxycholic acid (DCA),
chenodeoxycholic acid (CDCA), and cholic acid (CA) can
dose-dependently induce cAMP production in human TGR5-
transfected CHO cells. The rank order of potency (EC50) is
TLCA (0.33 µM) >LCA (0.53 µM) >DCA (1.01 µM) >CDCA
(4.43 µM) >CA (7.72 µM) (Kawamata et al., 2003) (Table 1).
Obacunone, as a limonoid, is found in Citrus. It can dose-
dependently stimulate the activity of TGR5 (Horiba et al., 2015).
Some other compounds such as linolenic acid (Katsuma et al.,
2005) and oleanolic acid (OA) are also identified as weak TGR5
ligands (Sato et al., 2007).
CDCA, DCA, LCA, ursodeoxycholic acid (UDCA) are not
only the activators of TGR5 but also the activators of farnesoid
X receptor (FXR) (Makishima et al., 1999; Wang et al.,
2008a,b). In order to find the specific and selective TGR5
ligands, multiple TGR5 agonists were designed and synthesized.
Pellicciari et al. reported 23-alkyl-substituted and 6, 23-alkyl-
disubstituted derivatives of CDCA are the selective agonists of
TGR5 (Pellicciari et al., 2007). 6α-ethyl-23(S)-methyl-cholic acid
(6-EMCA, INT-777) had been discovered as a selective, specific
agonist for TGR5 (Pellicciari et al., 2009, Table 1). Zhu et al.
(2013) designed a new class of potent TGR5 agonists based on
4-phenyl pyridine scaffold. After evaluated in vitro and in vivo,
three compounds showed good effects on activating TGR5. A
series of 4-benzofuranyloxynicotinamde derivatives were found
to be novel and potent TGR5 agonists (Zou et al., 2014, Table 1).
One of them has the highest activity in vitro (hTGR5 EC50 = 0.28
nM, mTGR5 EC50 = 0.92 nM). Zambad et al. (2013) synthesized
TRC210258 as a novel TGR5 agonist (Table 1). Zheng et al. found
small compoundWB403 could activate TGR5 and promote GLP-
1 secretion (Zheng et al., 2015).
TGR5 AND CELL SIGNALING
TGR5 and AKT Pathway
AKT is a serine/threonine kinase (Faes and Dormond, 2015).
It plays important roles in diverse cell processes including
differentiation, proliferation, survival, and metabolism
(Sasaki and Kuniyasu, 2014). AKT has pleckstrin homology
(PH) domain. At the plasma membrane, the interaction
between the PH domain of AKT and phosphatidylinositol
trisphosphate (PIP3) induces subsequent modifications of AKT
at threonine 308. AKT also can be phosphorylated at serine
473. Phosphorylated AKT inhibits pro-apoptotic members of
the Bcl-2 family, contributing to cell survival (Sarbassov et al.,
2005). In bovine aortic endothelial cells, treatment with TGR5
agonist TLCA enhances AKT phosphorylation and increases NO
production (Kida et al., 2013, Figure 1).
Mammalian target of rapamycin (mTOR) is one of the
key downstream effectors for the AKT signaling (Covarrubias
et al., 2015). mTOR is required for the translation of
proteins, which contribute to promoting cell survival and
proliferation. TGR5 can reduce chemokine expression via
AKT-mTOR pathway in macrophages (Perino et al., 2014).
AKT-mTOR pathway can be enhanced through the activation
of TGR5. mTOR exists as two complexes mTORC1 and
mTORC2. The phosphorylation of AKT and mTORC1 affects
the expression of eukaryotic translation initiation factor 4E-
binding protein 1 (4E-BP), which is involved in CCAAT-
enhancer-binding proteins (C/EBP)β isoform switching. After
TGR5 activation, mTORC1 increases the level of phosphorylated
4E-BP and the C/EBPβ isoform liver-inhibitory protein (LIP)
expression. The link between TGR5 and AKT-mTOR-LIP reveals
a new mechanism by which macrophages contribute to the
antidiabetic effects of TGR5 activation (Perino et al., 2014,
Figure 1).
TGR5 and NF-κB Pathway
NF-κB is a transcription factor connected with several cellular
processes such as inflammation, proliferation, apoptosis and
development (Wang et al., 2008c; Meng et al., 2011; Sarode
et al., 2015; Papademetrio et al., 2016). NF-κB comprises of five
members, RelA (p65), RelB, c-Rel, p50, and p52 (Sun et al.,
2013). They are kept inactive in the plasma by binding to family
members of IκB including IκBα, IκBβ, IκBγ, BCL3, IκBε, p105,
and p100 (DiDonato et al., 2012). Specific IKK kinase regulates
IκBα or IκBβ phosphorylation, resulting in activation of NF-κB
(Verstrepen and Beyaert, 2014). Two of TGR5 agonists, DCA
and LCA, can inhibit tumor necrosis factor-α production in
CD14+ macrophages (Yoneno et al., 2013). This inhibitory effect
is mediated by the phosphorylation of c-Fos to regulate NF-κB
p65 activation. Our group identified TGR5 negatively regulated
hepatic inflammatory response through antagonizing NF-κB
(Wang et al., 2011). We found TGR5 activation suppressed
the phosphorylation of IκBα, the translocation of p65, NF-
κB DNA binding activity and its transcription activity in
HepG2 cells. In the same year, Pols et al. found TGR5
activation by INT-777 decreased nuclear translocation of p65
and phosphorylation of IκBα in macrophages (Pols et al., 2011)
(Table 1, Figure 1).
TGR5 and Extracellular Signal-Regulated
Kinases (ERK) 1/2 Pathway
The kinases ERK1 and ERK2 are members of the mitogen-
activated protein kinase family (Pascoli et al., 2014). They
are involved in diverse cellular responses such as survival,
differentiation, and proliferation (Cheng et al., 2013). In
the recent report, Reich et al. (2016) shown that TGR5-
selective agonists induced cholangiocyte proliferation through
elevation of reactive oxygen species and proto-oncogene,
non-receptor tyrosine kinase (cSrc)-mediated epidermal
growth factor receptor transactivation and subsequent ERK1/2
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TABLE 1 | Summary of related TGR5 information.
Gene GPBAR1, 2q35
Expression in human tissues Placenta, Spleen, Small intestine, Stomach, Liver, Lung, Heart, Skeletal muscle, Kidney, Peripheral blood leukocytes
Natural agonists Name Structures References
Primary bile acid CA Kawamata et al., 2003
CDCA Kawamata et al., 2003
Secondary bile acid LCA Kawamata et al., 2003
TLCA Kawamata et al., 2003
DCA Kawamata et al., 2003
Natural phytochemical agonists Linolenic acid Katsuma et al., 2005
OA Sato et al., 2007
Obacunone Horiba et al., 2015
Synthetic agonists INT-777 Pellicciari et al., 2009
(Continued)
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TABLE 1 | Continued
Gene GPBAR1, 2q35
Expression in human tissues Placenta, Spleen, Small intestine, Stomach, Liver, Lung, Heart, Skeletal muscle, Kidney, Peripheral blood leukocytes
Natural agonists Name Structures References
TRC210258 Zambad et al., 2013
WB403 Zheng et al., 2015
Relevant diseases Agonists References
Type 2 diabetes LCA, DCA, Lionlenic acid, OA, INT-777,
WB403
Katsuma et al., 2005; Sato et al., 2007;
Perino et al., 2014; Zheng et al., 2015
Obesity CA, TCA, DCA, CDCA Watanabe et al., 2006
Inflammation Betulinic acid, 23(S)-mCDCA,
TLCA, TLC, CDCA, DCA
Kawamata et al., 2003; Keitel et al., 2008;
Wang et al., 2011; Mobraten et al., 2015;
Guo et al., 2015b; McMillin et al., 2015
Gastric cancer 23(S)-mCDCA, GPBARA Guo et al., 2015a
Liver regeneration CA Péan et al., 2013
phosphorylation in wild type mouse cells. In the ciliated
and non-ciliated cholangiocytes, TGR5 activation induces
different changes in the levels of cAMP and ERK (Masyuk et al.,
2013). TGR5 agonists increase cAMP level and inhibit ERK
signaling, resulting in inducing proliferation in non-ciliated
cholangiocytes. But in the ciliated cholangiocytes, TGR5 agonists
decrease cAMP level and induce ERK signaling, resulting in
inhibition of proliferation. The opposite effects of TGR5 agonists
are due to the coupling of TGR5 to Gαi protein in ciliated
cells and Gαs protein in non-ciliated cells (Masyuk et al., 2013,
Figure 1).
TGR5 and Signal Transducer and Activator
of Transcription 3 (STAT3) Pathway
STAT3 was at first found as a DNA-binding factor in interleukin-
6 (IL-6) stimulated hepatocytes. It is an enhancer element
in the promoter region of acute-phase genes (Akira et al.,
1994). As a transcription factor, STAT3 controls several cellular
processes including development, differentiation, immunity,
invasion, and metabolism (Kane et al., 2014; Teng et al., 2014;
Poli and Camporeale, 2015). It is overexpressed in pathological
conditions such as cancer (Yamanaka et al., 1996). Many
reports showed STAT3 is activated in various tumor cell lines
such as colon, gastric, lung, skin, and breast cancer cells
(Levy and Lee, 2002; Yin et al., 2006; Sansone et al., 2007;
Yoshimura et al., 2007). Our group found that TGR5 is a
suppressor of gastric cancer cell proliferation and migration
through antagonizing STAT3 signaling pathway (Guo et al.,
2015b). TGR5 activation antagonized STAT3 signaling pathway
through suppressing the phosphorylation of STAT3 and its
transcription activity induced by lipoplysaccharide (LPS) or IL-
6. It suggests that TGR5 antagonizes gastric cancer proliferation
and migration at least in part by inhibiting STAT3 signaling.
These findings identify TGR5 as an attractive therapeutic
target for treatment of gastric cancer (Guo et al., 2015a,b,
Figure 1).
TGR5 and Exchange Protein Directly
Activated by cAMP (Epac) Pathway
Epac is a member of guanine nucleotide exchange factor family
and an essential cAMP effector (Gloerich and Bos, 2010).
It has multiple binding factors, and is involved in several
cellular events (Breckler et al., 2011). In pancreatic β cells, the
activation of TGR5 by OA and INT-777 selectively activates
Gαs. And then the levels of intracellular cAMP and Ca
2+
will be increased. Epac but not protein kinase A (PKA) can
be activated by 8-pCT-2′-O-Me-cAMP, a cAMP analog, and
stimulates phosphoinositide (PI) hydrolysis. As the result of the
effect, insulin releases from pancreatic β cells (Kumar et al., 2012).
In enteroendocrine cells, TGR5 ligand OA can also stimulate Gαs
and cAMP formation, and activate Epac increasing PI hydrolysis,
glucagon-likepeptide1 (GLP-1) and Peptide YY (PYY) release
(Figure 1).
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FIGURE 1 | TGR5 regulates different cell signaling pathways. TGR5 activates AKT (Kida et al., 2013; Perino et al., 2014), TRPA1 (Lieu et al., 2014), and Epac
(Kumar et al., 2012) pathways. And it inhibits NF-κB (Pols et al., 2011; Wang et al., 2011; Yoneno et al., 2013), STAT3 (Guo et al., 2015b), and RhoA/Rho kinase
(Rajagopal et al., 2013) pathways. TGR5 has opposite functions in ERK1/2 pathway. In ciliated cholangiocytes, ERK1/2 is activated by TGR5 (Masyuk et al., 2013).
But in non-ciliated cholangiocytes, TGR5 activation inhibits ERK1/2 (Masyuk et al., 2013).
TGR5 AND DIFFERENT DISEASES
TGR5 and T2D
Diabetes is one of the fastest deadly growing diseases in the
world. T2D is the most common type of diabetes (Zarrinpar
and Loomba, 2012). The development of T2D is commonly
related to obesity, hypertension, and dyslipidemia (Goedecke
and Micklesfield, 2014; Maki and Phillips, 2015). These latter
complications promote the development of cardiovascular
disease (Johnston et al., 2014). And they are the most common
mortality linked to T2D. T2D is classically described as
a heterogeneous group of disorders, characterized by a
decline in insulin-producing pancreatic β cells, an increase
in peripheral insulin resistance, an increase in hepatic glucose
production, or a combination of all the factors (Alejandro
et al., 2015). Therapies for T2D are made based on reducing
hepatic glucose production, increasing insulin secretion,
and improving insulin sensitivity (Zarrinpar and Loomba,
2012).
Several studies show the importance of bile acids in glucose
homeostasis. Bile acids can improve glycemic control (Zarrinpar
and Loomba, 2012). TGR5 as a receptor of bile acids has effect
on the regulation of glucose metabolism. In 2005, the study of
Katsuma et al. shown the activation of TGR5 could promote
GLP-1 secretion in a murine enteroendocrine cell line STC-1
(Katsuma et al., 2005). GLP-1, as the incretin hormone, has the
incretin effect, which is the augmentation of insulin secretion
after oral administration of glucose. So GLP-1 plays an important
role in T2D (Sonne et al., 2014). The secretion of GLP-1 is
dose-dependent. The overexpression of TGR5 enhances the level
of cAMP and GLP-1 secretion. It suggests that TGR5 induces
GLP-1 secretion via intracellular cAMP production (Katsuma
et al., 2005). This study aroused the interest of many groups in
exploring potential treatment of T2D through the management
of glucose homeostasis by activating TGR5. In 2007, OA isolated
from olive leaves was found as a natural TGR5 agonist. It
decreased plasma glucose and insulin via the activation of TGR5
(Sato et al., 2007). Recent years, it is found that TGR5 induces
differential translation of the C/EBPβ isoform LIP by AKT-
mTOR pathway in macrophages. And the activation of TGR5 can
alter adipose tissue macrophage (ATM) function and improve
insulin action. So TGR5 activation in macrophages may prevent
insulin resistance and treat T2D (Perino et al., 2014, Table 1).
In 2015, a small compound WB403 was identified as a TGR5
agonist. It was tested in the different mouse models of T2D for
glycemic control. As a result, TGR5 could be activated byWB403
to improve glucose tolerance, decrease fasting blood glucose and
the glycosylated hemoglobin A1c (HbA1c) in T2D mice (Zheng
et al., 2015). In the new reports, Kumar et al. (2016) shown
that TGR5 induced GLP-1 release from pancreatic α cells via
an Epac-mediated PKA-independent mechanism. Agarwal et al.
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(2016) also shown the important roles of TGR5 in T2D. All of
these studies indicate the important functions of TGR5 in T2D
treatment.
TGR5 and Obesity
Obesity becomes great threat to public health in the world.
The energy intake exceeds expenditure, resulting in obesity
(Nalliah et al., 2016). It is now known that brown adipose
tissue (BAT) dissipates energy as heat by thermogenesis (Chen
et al., 2011). In human BAT, the mitochondria are powerful
generators of heat. It metabolizes fat, protecting people from
obesity. Because of the key role of BAT in energy burning,
increasing BAT amount could be used for treatment of obesity.
The administration of bile acids to mice can increase energy
expenditure in BAT. This effect is dependent on activation
of TGR5, but not FXR (Chen et al., 2011). TGR5 activation
increases the level of cAMP-dependent thyroid hormone-
activating enzyme, type 2 iodothyronine deiodinase (D2). D2
is one of major thermogenic protein. It can convert thyroxine
(T4) into active tri-iodothyronine (T3) in BAT. Bile acid
treatment in BAT and human skeletal muscle cells increases
D2 activity, oxygen consumption and extracellular acidification
rate (Watanabe et al., 2006). In the recent years, different
groups also show that the new roles of TGR5 in obesity
(Chen et al., 2015; Donepudi et al., 2016; Pierre et al.,
2016; Wang et al., 2016). For example, Wang et al. (2016)
reported TGR5 inhibited kidney disease in obesity and diabetes
through inducing mitochondrial biogenesis and preventing renal
oxidative stress and lipid accumulation. These reports suggest
that TGR5 agonists may be the potential drugs for treating
obesity.
TGR5 and Inflammation
Inflammation is one of the responses of the organism to
harmful stimuli, such as pathogens, damaged cells, or irritants
(Wang et al., 2008c; Meng et al., 2011). Chronic inflammation
is increasingly recognized as an important component of
tumorigenesis and metabolic diseases (Coussens and Werb,
2002). Therefore, the precise control of inflammation is essential
for the prevention of chronic inflammatory disorders, as well
as for inhibiting the exacerbation or progression of diseases,
including many types of cancers (Shacter and Weitzman, 2002;
Wang et al., 2011).
Our group found the activation of TGR5 could inhibit
inflammation in liver and stomach (Wang et al., 2011; Guo
et al., 2015a). In liver, TGR5 inhibits the expression of
inflammatory mediators in response to NF-κB activation
induced by LPS in wild-type (WT), but not TGR5−/− mice
(Wang et al., 2011). Yang et al. (2016) reported that during
ischemia/reperfusion injury TGR5 inhibited inflammatory
response through suppression of the Toll-like receptor 4
(TLR4)-NF-κB pathway. TGR5 activation can also suppress
LPS-induced production of cytokines in Kupffer cells and
TGR5-overexpressed THP-1 cells (Kawamata et al., 2003;
Keitel et al., 2008). But in human monocytes, co-triggering of
TGR5 and TLR4 enhances the activation of NF-κB and the
production of inflammatory cytokines. The two different and
simultaneous events associate with the function of human
monocytes, contributing to increasing inflammation (Mobraten
et al., 2015). Hepatic encephalopathy (HE) can be a major
neurological complication of acute and chronic liver failure. It
causes neuroinflammation. The activation of TGR5 by betulinic
acid decreases neuroinflammation via neuron and microglia
paracrine signaling during HE (McMillin et al., 2015, Table 1).
Last year, our group found that TGR5 activation also suppresses
gastric inflammation (Guo et al., 2015a). Chronic inflammation
is connected with various diseases such as liver, colon and
gastric cancer (Guo et al., 2015b). TGR5 may be a potential
target for treatment of chronic inflammation and related
cancer.
TGR5 and Cancer
Gastric cancer is one of the most common cancers in the
world. Gastric carcinogenesis is a complex process and
easily causes death (Lin et al., 2015). There are few reports
about TGR5 and cancer. Our group found that TGR5
activation could suppress gastric cancer cell proliferation
and migration via inhibiting STAT3 pathway (Guo et al.,
2015b). Han et al. (2014) demonstrated that the aberrant
hypermethylation of TGR5 promoter in serum cfDNA
might serve as a biomarker for the surveillance of HCC.
Hong et al. (2010) found that TGR5 receptor is over-
expressed in oesophageal adenocarcinoma tissues and
indicated TGR5 may play an important role in oesophageal
adenocarcinoma. The functions of TGR5 in other cancers need
to be investigated.
TGR5 and Liver Regeneration
Normal liver regeneration is important for restoring the liver
mass following liver injury. Previous reports indicate that 70%
hepatectomy increases BA flux and changes expression of several
nuclear receptors and enzymes involved in BA metabolism
(Wang et al., 2008a). The reports shown that bile salts are
important for liver regeneration following partial hepatectomy
through activating FXR and TGR5 (Wang et al., 2008c; Chen
et al., 2010; Fan et al., 2015). In TGR5 knockout mice,
exacerbated inflammatory response, severe hepatocyte necrosis,
prolonged cholestasis, and delayed regeneration was observed
after partial hepatectomy (Péan et al., 2013). So TGR5 has a
crucial protective role on the liver in case of BA overload after
partial hepatectomy through the control of bile hydrophobicity
and cytokine secretion (Zou et al., 2014; Jourdainne et al.,
2015).
Other Bile Acid Membrane Receptors
Bile acids also activate other two GPCRs sphingosine-1-
phosphate receptor 2 (S1PR2) and muscarinic receptor 2
(Chrm2) (Zhou and Hylemon, 2014). Conjugated bile acids
activate S1PR2 to regulate inflammation, cancer development
and some liver diseases (Kwong et al., 2015). Muscarinic
receptors are overexpressed in colon cancer and their activation
promotes proliferation, migration and invasion of human colon
cancer cells (Raufman et al., 2003, 2011).
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PROSPECTS
TGR5, as an important membrane receptor, is activated by bile
acids and multiple compounds. The novel roles of TGR5 in
different diseases make it become a new drug target. Further
investigation of TGR5 will provide novel insights into the
complex mechanism of metabolic diseases and cancer.
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